Colitis: Clinical Trials

3 trials for Colitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 enrolling by invitation. 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 43Enrolling by invitation 3

Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
INSIGHT-IBD Pragmatic Study
Mirikizumab, Anti-TNF agents, anti-integrin antibodies - Ulcerative Colitis (UC), Crohn Disease (CD)
Phase 4Enrolling by invitationSpecialty Networks Research.4002026-08-122026-10-29
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
PK-model to decide when to dose Vedolizumab and Ustekinumab - Inflammatory Bowel Diseases, Crohn Disease
Phase 4Enrolling by invitationOdense University Hospital1662026-01-232026-11-06
De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease
Infliximab, Adalimumab - Inflammatory Bowel Diseases, Crohn Disease
Phase 4Enrolling by invitationUniversity Medical Center Groningen1482021-03-112025-01-06

Narrower conditions

Colitis, Ulcerative (3)  ·  Crohn Disease (3)  ·  Inflammatory Bowel Diseases (2)

Broader conditions

Colonic Diseases (3)  ·  Digestive System Diseases (3)  ·  Gastroenteritis (3)  ·  Gastrointestinal Diseases (3)  ·  Intestinal Diseases (3)  ·  Inflammatory Bowel Diseases (1)

Interventions

Adalimumab (1)  ·  CT-P13 (1)  ·  Infliximab (1)  ·  Interleukin-12 (1)  ·  Interleukin-23 (1)  ·  Ustekinumab (1)  ·  mirikizumab (1)

Sponsors

Odense University Hospital (1)  ·  Specialty Networks Research. (1)  ·  University Medical Center Groningen (1)

Countries

Belgium (1)  ·  Denmark (1)  ·  Netherlands (1)  ·  Spain (1)  ·  United States (1)

Top investigators

Casey Chapman, MD (1)  ·  Mark A Ainsworth, professor, DMSc (1)  ·  Nicholas Lazarou, MPH, MBA (1)  ·  Patrick F van Rheenen, MD PhD (1)

Results publications

PMID 34732500, PMID 39390697, PMID 41453773